Data presented at ASH 2021 congress show 83 percent of patients achieved a stringent complete response at median follow-up of 22 months1 92 percent of evaluable patients achieved minimal residual
Eighteen-month follow-up data from pivotal CARTITUDE-1 study, including progression-free-survival data, to be presented at ASCO and EHA Annual Meetings Findings from the Phase 2 CARTITUDE-2 study
Janssen Receives Positive CHMP Opinion for SPRAVATO? (Esketamine Nasal Spray) for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder
vs 20.4%), respectively.
6 There is a pressing need to provide individuals with Major Depressive Disorder who are experiencing a psychiatric emergency with treatments that can rapidly reduce their depressive symptoms, said Bill Martin, Ph.D., Global Therapeutic Area Head, Neuroscience, Janssen Research Development, LLC. If approved by the European Commission, esketamine nasal spray has the potential to offer individuals relief from debilitating depressive symptoms and address a key unmet need within this population.
With this positive CHMP opinion, esketamine nasal spray will now be considered by the European Commission for adults with a moderate to severe episode of MDD, as acute, short term treatment, for the rapid reduction of depressive symptoms, which according to clinical judg